Diamanti A, Gambarara M, Knafelz D, Marcellini M, Boldrini R, Ferretti F, Papadatou B, Castro M
Gastroenterology Unit, Bambino Gesù Children Hospital, Piazza S. Onofrio 4, 00165 Rome, Italy.
Transplant Proc. 2003 Dec;35(8):3047-9. doi: 10.1016/j.transproceed.2003.10.037.
Parenteral nutrition (PN) is the only treatment for patients affected by chronic intestinal failure (CIF). Home parenteral nutrition (HPN) programs are started when patients need prolonged PN. Unfortunately, many patients on prolonged PN develop liver disease (LD). The aim of our study was to assess the prevalence of LD in our series of patients on HPN. We reviewed our records of patients discharged from the hospital on HPN for CIF. HPN was started when one parent was fully trained in the use of this treatment and if the social and familial home environment was reliable. All patients received total PN by a central venous catheter. All patients with abnormal AST, ALT, ALK, gammaGT, and bilirubin values for more than 3 months were considered affected by PN-related LD. Thirty-six patients (23 of whom were boys and 13 girls) were discharged on HPN. During the study period, for CIF, 16 were affected by short bowel syndrome (SBS), of whom 6 had ultra-short bowel; 16 with functional intestinal failure, and 4 with chronic intestinal pseudobstruction (CIPO). Mean duration of HPN was 2.1 years/patient. Nine of 36 patients (25%) on HPN for CIF showed LD. Seven of the 16 patients (43%) with LD were affected by SBS and 2 (12.5%) patients by functional intestinal failure. No patients with CIPO developed LD. In patients affected by SBS, the onset of LD was very earlier than in patients with ID.
肠外营养(PN)是慢性肠衰竭(CIF)患者的唯一治疗方法。当患者需要长期PN时,启动家庭肠外营养(HPN)计划。不幸的是,许多接受长期PN的患者会发生肝病(LD)。我们研究的目的是评估我们这组接受HPN治疗患者中LD的患病率。我们回顾了因CIF接受HPN治疗后出院的患者记录。当一位家长完全接受了这种治疗方法的培训且社会和家庭环境可靠时,才开始实施HPN。所有患者均通过中心静脉导管接受全肠外营养。所有谷草转氨酶(AST)、谷丙转氨酶(ALT)、碱性磷酸酶(ALK)、γ-谷氨酰转肽酶(gammaGT)和胆红素值异常超过3个月的患者被视为患有PN相关的LD。36例患者(其中23例为男孩,13例为女孩)接受HPN治疗后出院。在研究期间,因CIF接受治疗的患者中,16例患有短肠综合征(SBS),其中6例为超短肠;16例为功能性肠衰竭,4例为慢性肠假性梗阻(CIPO)。HPN的平均疗程为每位患者2.1年。36例因CIF接受HPN治疗的患者中有9例(25%)出现LD。16例患有LD的患者中,7例(43%)患有SBS,2例(12.5%)患有功能性肠衰竭。没有CIPO患者发生LD。在患有SBS的患者中,LD的发病比患有ID的患者早得多。